Perceptive Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History

Perceptive Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $19.7 Million - $24 Million	256,693 Added 46.22%	812,037 $74 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $25.9 Million - $37.2 Million	555,344 New	555,344 $36.6 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $2.02 Million - $3.14 Million	45,100 Added 14.04%	366,400 $25 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $40.7 Million - $68.7 Million	-1,160,400 Reduced 78.32%	321,300 $14.5 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $1.06 Million - $1.62 Million	30,000 Added 2.07%	1,481,700 $75.3 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $25.7 Million - $41.1 Million	836,700 Added 136.05%	1,451,700 $68.6 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $1.45 Million - $3.22 Million	-46,162 Reduced 6.98%	615,000 $20.3 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $27 Million - $42.9 Million	661,162 New	661,162 $41.8 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $295,612 - $384,215	-11,418 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $204,496 - $506,159	11,418 New	11,418 $327,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.